Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

Gary A. Levy ¹Kadalraja Raghavan Vidyasagar Devaprasad Dedeepiya Vaddi Suryaprakash Kosagi-Sharaf Rao Nobunao Ikewaki Tohru Sonoda Masaru Iwasaki Rajappa Senthilkumar Senthilkumar Preethy Samuel JK Abraham

扫码查看

作者信息

1. Dept of Paediatric Neurology, Kenmax Healthcare Services Pvt Ltd, Madurai, India
折叠

Abstract

Objective: In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coa-gulopathy in COVID-19 patients. Methods: A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr): Gr. 1 control (n = 8) - Standard treatment; Gr. 2: Standard treatment + AFO-202 beta glucan (n = 8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n = 8) for 30 days. Results: There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395-3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer: 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer: 560.99 ng/dl to 79.615; IL-6: 26.18-3.41 pg/ml) and 3 (D-dimer: 1614 ng/dl to 164.25 ng/dl; IL-6: 6.25-0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4 + and CD8 + T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups. Conclusion: As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.

Key words

COVID-19/IL-6/D-dimer/Cytokine storm/Coagulopathy/Immuno-modulation/Beta glucans/Adjunct treatment

引用本文复制引用

出版年

2022

Biomedicine & pharmacotherapy

SCI

ISSN：0753-3322

段落导航